diabetic macular edema
Conditions
Interventions
Test group:Conbercept Injection + Xiaozhong granules
Control group:Conbercept Injection +Placebo granules
Sponsors
Eye Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Synergistic Chinese and Western medicine treatment program, Synergistic Chinese and Western medicine low vision rehabilitation program. (1) Those with poorly cleared refractive interstitium and difficulty in fundus observation. (2) Those who have already undergone vitreous cavity injection of anti-VEGF or hormonal drugs, gridded photocoagulation, local photocoagulation, or total retinal photocoagulation within 3 months after any one or more of these treatment modalities. (3) Those with combined fundus disease such as glaucoma, retinal vein obstruction, uveitis, or optic nerve disease. (4) Patients with combined severe cardiovascular, hepatic and hematopoietic system diseases and diabetic nephropathy with renal failure; HBA1c = 10% and liver and kidney function test results exceeding 1.5 times normal (5) Patients with combined serious life-threatening primary diseases and psychiatric disorders (6) Pregnant or lactating women. (7) Those who are participating in clinical trials of other drugs or are taking drugs that may affect the clinical evaluation of this study. (8) Inability to cooperate during the examination and to adhere to the follow-up fundus examination.
Exclusion criteria
Exclusion criteria: Synergistic Chinese and Western medicine treatment program, Synergistic Chinese and Western medicine low vision rehabilitation program. (1) Those with poorly cleared refractive interstitium and difficulty in fundus observation. (2) Those who have already undergone vitreous cavity injection of anti-VEGF or hormonal drugs, gridded photocoagulation, local photocoagulation, or total retinal photocoagulation within 3 months after any one or more of these treatment modalities. (3) Those with combined fundus disease such as glaucoma, retinal vein obstruction, uveitis, or optic nerve disease. (4) Patients with combined severe cardiovascular, hepatic and hematopoietic system diseases and diabetic nephropathy with renal failure; HBA1c = 10% and liver and kidney function test results exceeding 1.5 times normal (5) Patients with combined serious life-threatening primary diseases and psychiatric disorders (6) Pregnant or lactating women. (7) Those who are participating in clinical trials of other drugs or are taking drugs that may affect the clinical evaluation of this study. (8) Inability to cooperate during the examination and to adhere to the follow-up fundus examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Macular central fovea thickness;Best corrected visual acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| macular area no vascular area;Fixation stability;macular area blood flow density;TCM syndrom score; macular retinal sensitivity; | — |
Countries
China
Contacts
Public ContactChuanhong Jie
Outcome results
None listed